UMIN-CTR Clinical Trial

Basic information
Public title	Efficacy and Safety of Ombitasvir plus Paritaprevir/r combination regimen for Hepatitis C infected patients with immune disorders
Acronym	Ombitasvir /Paritaprevir/r therapy for patients with immune disorders
Scientific Title	Efficacy and Safety of Ombitasvir plus Paritaprevir/r combination regimen for Hepatitis C infected patients with immune disorders
Scientific Title:Acronym	Ombitasvir /Paritaprevir/r therapy for patients with immune disorders
Region	Japan

Condition
Condition	Patients with genotype 1 HCV infection who have immune disorder
Classification by specialty	Hepato-biliary-pancreatic medicine
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	To evaluate efficacy (SVR12 rate) and safety of Ombitasvir / Paritaprevir/rtherapy in CHC patients with immune disorders (cryoglobulinemia or Sjogrens syndrome)
Basic objectives2	Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	To evaluate efficacy (SVR12 rate) and safety of Ombitasvir / Paritaprevir/r therapy in CHC patients with immune disorders (cryoglobulinemia or Sjogrens syndrome)
Key secondary outcomes	To assess the effect of HCV treatment on the status of immune disorders (cryoglobulinemia or Sjogrens syndrome). 2)mutations as viral factors on virologic response 3) Rate of emergence of drug-resistant variants 4) Presence or absence of a reversal of liver fibrosis 5) Presence or absence of an improvement in AFP levels 6) Effects of glucose/lipid-related factors on treatment response

Base
Study type	Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	20 years-old <=
Age-upper limit	Not applicable
Gender	Male and Female
Key inclusion criteria	Patients (1) with the target disease who (2) satisfy all the inclusion criteria and (3) meet none of the exclusion criteria are eligible for the study. (1) Subjects Patients with immune disorder, who have a chronic HCV infection and compensated cirrhosis (2) Inclusion criteria [1] Patients who are 20 years of age or older at the time of informed consent [2] Patients who have been fully informed and have provided written informed consent to participate in this study prior to study initiation [3] Patients with a chronic HCV genotype 1 infection and compensated cirrhosis who do not meet any of the following exclusion criteria
Key exclusion criteria	1) Patients with poorly controlled cardiac disease (e.g., myocardial infarction, cardiac failure, arrhythmia) 2) Patients with severe hepatic impairment 3) Patients with a history of hypersensitivity to HCV protease inhibitors or NS5A inhibitor 4) Patients with a concurrent malignancy, including hepatocellular carcinoma, at the start of treatment 5) Patients deemed unsuitable for study entry by their treating physician 6) Patients who are unsuitable, in the opinion of the principal investigator, for this study due to any other reason
Target sample size	50

Research contact person
Name of lead principal investigator	1st name Middle name Last name Goki Suda
Organization	Hokkaido University
Division name	Department of Gastroenterology and Hepatology, Graduate School of Medicine,
Zip code
Address	Kita 14-jo Nishi 5-jo, Kita-ku, Sapporo city, Hokkaid
TEL	+81-11-716-1161
Email	gsudgast@pop.med.hokudai.ac.jp

Public contact
Name of contact person	1st name Middle name Last name Goki Suda
Organization	Hokkaido University
Division name	Department of Gastroenterology and Hepatology, Graduate School of Medicine,
Zip code
Address	Kita 14-jo Nishi 5-jo, Kita-ku, Sapporo city, Hokkaid
TEL	+81-11-716-1161
Homepage URL
Email	gsudgast@pop.med.hokudai.ac.jp

Sponsor
Institute	Hokkaido University
Institute
Department

Funding Source
Organization	AbbVie GK
Organization
Division
Category of Funding Organization	Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2015 Year 12 Month 24 Day

Related information
URL releasing protocol
Publication of results	Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status	Completed
Date of protocol fixation	2015 Year 12 Month 24 Day
Date of IRB	2015 Year 12 Month 24 Day
Anticipated trial start date	2016 Year 01 Month 04 Day
Last follow-up date	2019 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information	This study is cohort study Way for subscription Patients who visit our hospital between November 2015 and march 2017, and meet inclusion criteria are enrolled.

Management information
Registered date	2015 Year 12 Month 21 Day
Last modified on	2020 Year 01 Month 07 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023442